Baseline demographic and clinical features at diagnosis
| . | N . | % . |
|---|---|---|
| Stage before commencing ibrutinib | ||
| I/II | 10/140 | 7.1% |
| III/IV | 130/140 | 92.9% |
| Extranodal involvement | 78/140 | 55.7% |
| B symptoms | 58/139 | 41.7% |
| Bulk (>5cm based on most recent staging) | 40/139 | 28.8% |
| MCL histology subtype | ||
| WHO aggressive, blastoid | 13/149 | 8.7% |
| WHO aggressive, pleomorphic | 6/149 | 4.0% |
| WHO other, small cell | 26/149 | 17.4% |
| Non-WHO, leukemic non-nodal | 3/149 | 2.0% |
| Non-WHO, in situ | 1/149 | 0.7% |
| No subtype specified | 100/149 | 67.1% |
| ECOG PS | ||
| 0-1 | 106/141 | 75.2 |
| 2/3/4 | 35/141 | 24.8 |
| ASCT candidate | 11/123 | 8.9% |
| Ki67/MiB1 % | ||
| 0-29 | 56/95 | 58.9% |
| 30-49 | 15/95 | 15.8% |
| 50-100 | 24/95 | 25.3% |
| TP53 status (n = 48) | ||
| TP53 negative | 29/48 | 60.4% |
| TP53 positive | 19/48 | 39.6% |
| TP53 mutation | 10/149 | 6.7% |
| TP53 deletion | 7/149 | 4.7% |
| p53 overexpression | 2/149 | 1.3% |
| Not tested | 54/149 | 36.2% |
| Missing data | 47/149 | 31.5% |
| sMIPI | ||
| 0-3 | 18/135 | 13.3% |
| 4-5 | 49/135 | 36.3% |
| ≥6 | 68/135 | 50.4% |
| ≥1 high-risk disease feature | 54/149 | 36.2% |
| 1 high-risk feature | 36/149 | 24.2% |
| Ki67/MiB1 ≥30% | 24/149 | 16.1% |
| Blastoid/pleomorphic histology | 5/149 | 3.4% |
| p53/TP53 positive | 7/149 | 4.7% |
| 2 high-risk features | 13/149 | 8.7% |
| Ki67/MiB1 ≥30% and blastoid/ pleomorphic histology | 6/149 | 4.0% |
| Ki67/MiB1 ≥30% and p53/TP53 positive | 4/149 | 2.7% |
| Blastoid/pleomorphic histology and p53/TP53 positive | 3/149 | 2.0% |
| 3 high-risk features | 5/149 | 3.4% |
| . | N . | % . |
|---|---|---|
| Stage before commencing ibrutinib | ||
| I/II | 10/140 | 7.1% |
| III/IV | 130/140 | 92.9% |
| Extranodal involvement | 78/140 | 55.7% |
| B symptoms | 58/139 | 41.7% |
| Bulk (>5cm based on most recent staging) | 40/139 | 28.8% |
| MCL histology subtype | ||
| WHO aggressive, blastoid | 13/149 | 8.7% |
| WHO aggressive, pleomorphic | 6/149 | 4.0% |
| WHO other, small cell | 26/149 | 17.4% |
| Non-WHO, leukemic non-nodal | 3/149 | 2.0% |
| Non-WHO, in situ | 1/149 | 0.7% |
| No subtype specified | 100/149 | 67.1% |
| ECOG PS | ||
| 0-1 | 106/141 | 75.2 |
| 2/3/4 | 35/141 | 24.8 |
| ASCT candidate | 11/123 | 8.9% |
| Ki67/MiB1 % | ||
| 0-29 | 56/95 | 58.9% |
| 30-49 | 15/95 | 15.8% |
| 50-100 | 24/95 | 25.3% |
| TP53 status (n = 48) | ||
| TP53 negative | 29/48 | 60.4% |
| TP53 positive | 19/48 | 39.6% |
| TP53 mutation | 10/149 | 6.7% |
| TP53 deletion | 7/149 | 4.7% |
| p53 overexpression | 2/149 | 1.3% |
| Not tested | 54/149 | 36.2% |
| Missing data | 47/149 | 31.5% |
| sMIPI | ||
| 0-3 | 18/135 | 13.3% |
| 4-5 | 49/135 | 36.3% |
| ≥6 | 68/135 | 50.4% |
| ≥1 high-risk disease feature | 54/149 | 36.2% |
| 1 high-risk feature | 36/149 | 24.2% |
| Ki67/MiB1 ≥30% | 24/149 | 16.1% |
| Blastoid/pleomorphic histology | 5/149 | 3.4% |
| p53/TP53 positive | 7/149 | 4.7% |
| 2 high-risk features | 13/149 | 8.7% |
| Ki67/MiB1 ≥30% and blastoid/ pleomorphic histology | 6/149 | 4.0% |
| Ki67/MiB1 ≥30% and p53/TP53 positive | 4/149 | 2.7% |
| Blastoid/pleomorphic histology and p53/TP53 positive | 3/149 | 2.0% |
| 3 high-risk features | 5/149 | 3.4% |
ASCT, autologous SCT; PS, performance status; non-WHO, other subtype not included in WHO classification; WHO, World Health Organization.